Reference list

MACS® GMP ExpAct Treg Kit

Performance/ Expansion data

A Rapamycin-based GMP Compatible Process for the Isolation and Expansion of Regulatory T cells for Clinical Trials
Fraser H., Safinia N., Grageda N., Thirkell S., Lowe K., Fry L., Scotta C., Hope A., Fisher C., Hilton R., Game D., Harden P., Bushell A., Wood K., Lechler R.I., Lombardi G.
Molecular Therapy Methods and Clinical Development (2018)

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders.
Wiesinger M., Stoica D., Roessner S., Lorenz C., Fischer A., Atreya R., Neufert C. F., Atreya I., Scheffold A., Schuler-Thurner B., Neurath M. F., Schuler G. and Voskens C. J.
Front. Immunol. (2017) 8:1371. doi: 10.3389/fimmu.2017.01371

Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis.
Voskens C.J., Fischer A., Roessner S., Lorenz C.,Hirschmann S., Atreya R., Neufert C., Atreya I., Neurath M., Schuler G.
Inflamm Bowel Dis (2017) 23:1348–1359

Clinical-Grade Expanded Tregs Prevent GvHD While Allowing a Powerful T-Cell Dependent GvL Effect in Murine Models.
Del Papa B, Ruggeri L, Urbani E, Baldoni S, Cecchini D, Zei T, Iacucci Ostini R, Crescenzi B, Carotti A, Pierini A, Sportoletti P, Di Bartolomeo P, Falzetti F, Mecucci C, Velardi A, Martelli MF, Di Ianni M.
Biology of Blood and Marrow Transplantation (2017)

GMP validation of large-scale expansion of regulatory T cells from patients affected by liver and kidney failure.
C. Lavazza, M. Viganò, T. Montemurro, E. Montelatici, S. Budelli, M. G. Cannone, S. Savelli, F. Ulbar, L. Catani, V. Giudice, M. Cescon, G. La Manna, R. M. Lemoli, R. Giordano.
ISCT Meeting (2017) poster presentation

Utilization of leukapheresis and CD4 positive selection in Treg isolation and the ex-vivo expansion for a clinical application in transplantation and autoimmune disorders.
Gołąb K., Grose R., Trzonkowski P., Wickrema A., Tibudan M., Marek-Trzonkowska N., Matosz S., Solomina J., Ostrega D., Millis J. M., Witkowski P.
Oncotarget. (2016) Nov 29; 7(48): 79474–79484.

A robust, good manufacturing practice–compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. Alsuliman, A., Appel, S.H., Beers, D.R., Basar, R., Shaim, H., Kaur. I., Zulovich, J., Yvon, E., Muftuoglu, M., Imahashi, N., Kondo, K., Liu, E., Shpall, E.J., Rezvani, K. Cytotherapy. (2016) Oct;18(10):1312-24

Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation. Safinia N, Vaikunthanathan T, Fraser H, Thirkell S, Lowe K, Blackmore L, Whitehouse G, Martinez-Llordella M, Jassem W, Sanchez-Fueyo A, Lechler RI, Lombardi G. Oncotarget. (2016) Jan 17.

Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.
Theil A, Tuve S, Oelschlägel U, Maiwald A, Döhler D, Oßmann D, Zenkel A, Wilhelm C, Middeke JM, Shayegi N, Trautmann-Grill K, von Bonin M, Platzbecker U, Ehninger G, Bonifacio E, Bornhäuser M.
Cytotherapy. (2015) Apr;17(4):473-86.

Clinical-grade separation and expansion of regulatory T cells for clinical studies on cell therapy in solid organ transplantation. Fazekasova H., Thirkell,S. Lowe K., Bushell A., and Lombardi G. MACS&more Vol 15 – 2/2013

Clinical scale enrichment and expansion of highly pure CD25+FoxP3 regulatory T cells.
Conrads, C., Schmitz, J., Assenmacher, M., Niemand, C., Scheffold, A.
ASH Meeting, (2010), Poster abstract 3718.

Clinical-grade regulatory T cells: Comparative analysis of large scale expansion conditions. Velaga, S., Alter, C., Dringenberg, U., Thiesler, C.T., Kuhs, S., Olek, S., Ukena, S.N., Franzke, A. Experimental Hematology (2016) Sep 27. pii: S0301-472X(16)30620-8

Miltenyi Biotec provides products and services worldwide. Visit **www.miltenyibiotec.com/local** to find your nearest Miltenyi Biotec contact.

The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, MACS, and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in countries worldwide.

